Printer Friendly

Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.

Tokyo, Japan, May 17, 2006 - (JCN) - Eisai announced on May 16 that its UK subsidiary Eisai Ltd. has filed an application for ARICEPT (donepezil HC1 tablet) with the Medicines and Healthcare Products Regulatory Agency of the UK.

The company intends to seek approval in 12 European countries under the Mutual Recognition procedure.

Eisai expects that ARICEPT will become available for the treatment of severe Alzheimer's disease. Currently, about 4.5 million people have Alzheimer's disease in Europe.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 17, 2006
Words:87
Previous Article:Hitachi Develops Innovative Mass Spectrometry Method for Improving Accuracy in Protein Analysis.
Next Article:Olympus to Release Special Reagent Kit for Its Single Molecular Fluorescence Spectroscopy MF20.


Related Articles
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.
Asahi Kasei Pharma and Eisai in Sales Promotion Agreement for Eril in China.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |